2World Health Organization. Global tuberculosis Control. WHO report 2001.Geneva, Switzerland WHO/CDS/TB,2001:287.
3Kobashi Y,Yoneyama H,Okimoto N,et al.Clinical analysis of pulmonary tuberculosis in association with cor-ticosteroid therapy. Kekkaku . 1999
4A. Lalvani.Diagnosing tuberculosis infection in the 21st century — new tools to tackle an old enemy. Chest . 2007
5JG Erdozain,G Ruiz-Irastorza,MV Egurbide,A Martinez-Berriotxoa,C Aguirre.High risk of tuberculosis in systemic lupus erythematosus?. Lupus . 2006
6A Pratt,K Nicholl,L Kay.Use of the QuantiFERON TB gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience. Rheumatology . 2007
7DY Chen,GH Shen,TY Hsieh.Effectiveness of the combination of whole blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis and Rheumatism . 2008
8Dye C. Consensus statement. Global burden of tuberculosis: estimatedincidence, prevalence, and mortality by country. WHO Global Sur- veiUance and Monitoring Project[ J ]. JAMA, 1999. 282 (7) :677-86.
9Keane J. Tuberculosis associated with infliximab, a tumor necrosis fac- tor alpha-neutralizing agent [ J ]. N Engl J Med, 2001, 345 (15) : 1098-1104.
10Solovic, I. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J, 2010. 36(5) :1185-1206.
